Ephedrine Arsan


Manufacturer: Husnu Arsan Ilaclari AS Turkey
Category: Ephedrine HCL
Substance: Ephedrine
Package: 50 mg 20 tablets

Product Description

Ephedrine is widely used in sports and nutrition. When combined with caffeine and aspirin is the best burners of fat and stimulating agent, doping.
Active substance: ephedrine hydrochloride.
Product: pills in a blister pack – 20 pieces.
Shelf life: 5 years.
Manufacturer: Husnu Arsan Ilaclari AS Turkey
You can also buy another similar drug based on ephedrine, ephedrine hydrochloride or pseudoephedrine:

Sympathomimetic stimulates alpha and beta-adrenergic receptors. Acting on
varicose thickening adrenergic efferent fibers, promotes
release of norepinephrine into the synaptic cleft. In addition, having weak
combat stimulating effect directly on adrenergic receptors. It causes
vasoconstriction, bronchodilatory and stimulating effect.
Improves systemic blood pressure and peripheral vascular resistance, increases IOC, heart rate and force of heart juice-
increment, improves AV conduction; increases the tone of the skeletal muscles, kontse-
ntratsiyu glucose in the blood; inhibits peristalsis extends
pupil (without affecting the accommodation and intraocular pressure). It stimulates the
central nervous system, stimulating effect on close to fenaminu. It stops the activity
of MAO and catecholamine-O-methyltransferase. It has a stimulating
effect on alpha-adrenergic receptors of the blood vessels in the skin, causing a
narrowing of the blood vessels, thus reducing the their increased permeability,
resulting in the reduction of edema with urticaria. Start of therapeutic
effect after oral administration – after 15-60 minutes, the duration of action
tions – 3-5 hours, with a / m administration of 25-50 mg – 10-20 minutes, and 0.5-1 h corresponding
tively. With the re-introduction with a short interval (10-30 minutes) pres-
weed effect ephedrine decreases rapidly (tachyphylaxis occurs, the Holy
ciated with progressive decrease in norepinephrine reserves varicose


Rhinitis (including catarrhal, vasomotor), sinusitis, hay fever, arterial
tion hypotension (collapse, shock, surgery, spinal
anesthesia, trauma, hemorrhage, bacteremia, overdose gangliob-
lokiruyuschih, blockers and other antihypertensive drugs.); bronchial
asthma, urticaria, serum sickness (as part of combination thera-
FDI); narcolepsy, depression, sleeping drugs and poisoning drug,
bleeding from the gums and tooth pulp; Diagnosis in Ophthalmology (for
pupil dilation).


Hypersensitivity, insomnia, GOKMP, pheochromocytoma, fibrillation of
ventricles, uncontrolled hypertension and tahikardiya.C
caution. Metabolic acidosis, hypercapnia, hypoxia, mertsatel-
tion arrhythmia, angle-closure glaucoma, pulmonary hypertension, gipovole-
mia, myocardial infarction, occlusive vascular disease (including anam-
neze): arterial embolism, atherosclerosis, Buerger’s disease, frostbite,
diabetic endarteritis, Raynaud’s disease; CCC disease (including angina
pectoris, tachyarrhythmia, ventricular arrhythmia, coronary insufficiency,
hypertension), diabetes, hyperthyroidism, benign
vennaya prostatic hyperplasia, the simultaneous use of
funds for inhalation anesthesia.

Side effects:

From the nervous system:
more often – headache, sleep disturbance; less often – fatigue, ner-
voznost, restlessness, dizziness; Frequency unknown
at – convulsions, muscle spasms, tremors, numbness of the hands or feet, sleepiness;
when used in high doses – hallucinations, mood changes, or
From the CCC: less often – angina pectoris, bradycardia, or tachy
cardia, palpitations, increased or decreased blood pressure at high doses –
ventricular arrhythmias; rarely – discomfort or pain in the rib
cage; the frequency is unknown – unusual bleeding, redness of the skin
From the digestive system: more often – nausea, vomiting;
less frequently – dryness or irritation of the mouth or throat (with parenteral
parenterally application), loss of appetite; the frequency is unknown – heartburn.
From the urinary system:
less often – shortness, and painful urination.
Local reactions: pain or a burning sensation in the ground / im injection.
Others: less often – sweating, pale skin;
peripheral vasoconstriction, allergic reactions, shortness of breath or hindered
nennoe breath, chills, hyperthermia, mydriasis, blurred zrit-
Yelnia perception.


Symptoms: severe weakness, agitation, insomnia, urinary retention,
excessive increase in blood pressure, loss of appetite, vomiting, increased potootde-
tion, rash.
Treatment: the excessive hypertensive effect of reducing the rate of introduction
of the introduction or temporarily discontinued if ineffective – alpha-adrenergic
blockers are short-acting.

Special instructions:

When infusion device to be used with a measuring device
in order to control the infusion rate. Infusions should be carried out in
a large (preferably in the center) vein. During treatment recommended changes
renie blood pressure, urine volume, IOC, ECG, central venous pressure, the pressure
of the pulmonary artery wedge pressure in the pulmonary capillaries.
In order to avoid the development of nocturnal sleep disturbances should not be given efed-
rin and drugs containing it at the end of the day and before bedtime. Recommended compliance
to give care to avoid contact with the drug in the perivascular
tissue, which can cause their death (in the case of education extravasates,
immediately produce infiltration of 10-15 ml of 0.9% NaCl, containing
conductive 5-10 ml phentolamine). Excessive doses of myocardial infarction may
exacerbate ischemia by increasing myocardial oxygen demand. Before
the start of treatment as possible should be ‘corrected hypovolemia.
Ephedrine treatment did not substitute for blood transfusion, plasma, krovezameschayu-
ing liquids and / or salt solutions. Ephedrine is impractical to use
long (peripheral vasoconstriction, resulting in possible different
opment necrosis or gangrene). When assigning to correct arterial
hypotension or added to the solution of local anesthetics during
childbirth / delivery, as well as the co-administration with certain
drugs that stimulate generic activities (eg vasopressin, ergotamine,
ergonovine, metilergonovin) can cause resistant arterial giperten-
Zia (up to rupture of cerebral vessels); during spinnomozgo-
howling anesthesia, it can increase the heart rate of the fetus.
If the blood pressure in the mother is greater than 130/80 mm Hg, ephedrine use does not re-
mended. In connection with the stimulating effect on the central nervous system can be predme-
that addicts abuse. Upon termination of the treatment the dose should be
reduced gradually, as sudden cancellation of therapy may lead to
severe hypotension. If the opaque solution, it can not be entered.
The unused portion should be destroyed. Ephedrine oral
previously been used for the treatment of enuresis, and myasthenia gravis, but is now
replaced with a more effective means. MAO Inhibitors, increasing pressor-
ny sympathomimetic effects, may contribute to the occurrence of head
pain, arrhythmia, vomiting, hypertensive crisis, so when taking patient
ents of MAO inhibitors in the preceding 2-3 weeks sympathomimetic dose
should be reduced (1/10 part of the normal dose).